N-methyl-D-aspartate (NMDA) Enhancers' Benefit to Schizophrenia Treatment.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Sarcosine (Primary) ; NMDA receptor agonists
- Indications Schizophrenia
- Focus Adverse reactions; Therapeutic Use
- 08 Jul 2014 Biomarkers information updated
- 18 Nov 2013 Planned end date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 04 Sep 2012 Planned End Date changed from 1 Mar 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.